Jared Gollob, MD

Articles by Jared Gollob, MD

STAT6 Degradation by KT-621 Correlates With Itch and Lesion Reduction in AD

ByJared Gollob, MD,Kaitlyn Bader, Assistant Managing Editor

June 3rd 2026

Jared Gollob, MD, discusses phase 1b biomarker findings for KT-621, a STAT6 degrader in atopic dermatitis, presented at SID 2026.

85% of Biologic-Eligible AD Patients Left Behind — Can KT-621 Reach Them?

ByMaddi Hebebrand, MC, Associate Editor,Jared Gollob, MD

April 1st 2026

The ongoing phase 2b BROADEN2 study will evaluate KT-621 across 3 dose levels in 200 patients over 16 weeks, with results expected to guide phase 3 dose selection.

KT-474 Demonstrates Efficacy and Promise in Atopic Dermatitis and Hidradenitis Suppurativa Study

ByEmma Andrus, Associate Editor,Jared Gollob, MD

November 20th 2023

Jared Gollob, MD, Chief Medical Officer of Kymera Therapeutics, spoke with Dermatology Times to discuss these trial results.

Latest Updated Articles

85% of Biologic-Eligible AD Patients Left Behind — Can KT-621 Reach Them?
April 1st 2026

Jared Gollob, MD

Articles by Jared Gollob, MD

STAT6 Degradation by KT-621 Correlates With Itch and Lesion Reduction in AD

85% of Biologic-Eligible AD Patients Left Behind — Can KT-621 Reach Them?

KT-474 Demonstrates Efficacy and Promise in Atopic Dermatitis and Hidradenitis Suppurativa Study

Latest Updated Articles

Trending on Dermatology Times

Dermalogica Enters Medical Aesthetics with FDA-Cleared Microneedling PRO Pen

Social Media Mythbusters: Hypochlorous Acid Sprays

Topical GX-03 Hits 92.6% EASI-50 at Week 4 in Phase 2 AD Interim

Quoin Submits First-Ever IND Application for Peeling Skin Syndrome Therapy

Orally Bioavailable Superoxide Dismutase as an Adjunct in Dermatology: Mechanisms, Evidence, and Patient Selection